Who Exports Liraglutide from India — 53 Suppliers Behind a $4.3M Market
India's liraglutide export market is supplied by 53 active exporters who collectively shipped $4.3M across 416 shipments. SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with a 52.6% market share, followed by ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMI and LUPIN LIMITED. The top 5 suppliers together control 98.1% of total export value, reflecting a concentrated market structure.
Top Liraglutide Exporters from India — Ranked by Export Value
SUN PHARMACEUTICAL INDUSTRIES LIMITED is the leading liraglutide exporter from India, holding a 52.6% share of the $4.3M market across 416 shipments from 53 exporters. The top 5 suppliers — SUN PHARMACEUTICAL INDUSTRIES LIMITED, ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMI, LUPIN LIMITED, ABBOTT INDIA LIMITED, ONESOURCE SPECIALTY PHARMA LIMITED — collectively control 98.1% of total export value, indicating a highly concentrated market. Individual shares are: SUN PHARMACEUTICAL INDUSTRIES LIMITED (52.6%), ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMI (43.9%), LUPIN LIMITED (0.8%), ABBOTT INDIA LIMITED (0.5%), ONESOURCE SPECIALTY PHARMA LIMITED (0.3%).
Top Liraglutide Exporters from India
Ranked by export value · 53 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | SUN PHARMACEUTICAL INDUSTRIES LIMITED DIAVIC INJ 6MG/ML 2X1'S PEN NL -GST INVOICE NODIAVIC INJECTION 6MG/ML [1304 PACK X 1X10'S]DIAVIC INJ 6MG/ML 3X1'S PEN SE -GST INVOICE NO | $2.3M | 4 | 52.6% |
| 2 | ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMI GILIPTRA 6MG/ML 3X 3ML PREFILLED PENGILIPTRA 6MG/ML 2X 3ML PREFILLED PENSAXENDA INJECTION# | $1.9M | 9 | 43.9% |
| 3 | LUPIN LIMITED DIAVIC INJ 6MG/ML 2X1'S PEN NL -GST INVOICE NODIAVIC INJECTION 6MG/ML [1304 PACK X 1X10'S]DIAVIC INJ 6MG/ML 3X1'S PEN SE -GST INVOICE NO | $35.4K | 3 | 0.8% |
| 4 | ABBOTT INDIA LIMITED VICTOZA LIRAGLUTIDE H.L.MEDICINENOSVICTOZA LIRAGLUTIDE H.L.MEDICINEVICTOZA LIRAGLUTIDE BAT | $20.0K | 1 | 0.5% |
| 5 | ONESOURCE SPECIALTY PHARMA LIMITED LIRAGLUTIDE 6MG/ML SOLUTION FOR INJECTIONLIRAGLUTIDE INJECTION 6 MG/ML.NOSLIRAGLUTIDE 6 MG/ML SOLUTION FOR INJECTION | $11.7K | 4 | 0.3% |
| 6 | REGALIA LIFE SCIENCE PRIVATE LIMITED LIRAGLUTIDE 6MG/ML SOLUTION FOR INJECTION | $8.1K | 1 | 0.2% |
| 7 | VIOTONIC MEDICATION | $4.9K | 1 | 0.1% |
| 8 | ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED GILIPTRA 6MG/ML 3X 3ML PREFILLED PENGILIPTRA 6MG/ML 2X 3ML PREFILLED PENSAXENDA INJECTION# | $4.8K | 1 | 0.1% |
| 9 | MOVID IMPEX DIAVIC INJ 6MG/ML 2X1'S PEN NL -GST INVOICE NODIAVIC INJECTION 6MG/ML [1304 PACK X 1X10'S]DIAVIC INJ 6MG/ML 3X1'S PEN SE -GST INVOICE NO | $4.8K | 2 | 0.1% |
| 10 | RUTVA MEDICARE | $4.4K | 1 | 0.1% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Liraglutide exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | Warning Letter issued in | Yes, as of September | Yes | Not verified | Received FDA Warning Letter for CGMP violations at Dadra facility in June 2024. |
| Lupin Limited | Approved | Yes | Yes | Multiple | Received FDA approval for Travoprost Ophthalmic Solution in May 2024. |
| Abbott India Limited | Approved | Yes | Yes | Multiple | Holds multiple FDA approvals and maintains WHO-GMP and EU GMP certifications. |
| Orbicular Pharmaceutical Technologies Private Limited | Approved | Yes | Yes | Multiple | Holds multiple FDA approvals and maintains WHO-GMP and EU GMP certifications. |
| Onesource Specialty Pharma Limited | Approved | Yes | Yes | Multiple | Holds multiple FDA approvals and maintains WHO-GMP and EU GMP certifications. |
| Regalia Life Science Private Limited | Approved | Yes | Yes | Multiple | Holds multiple FDA approvals and maintains WHO-GMP and EU GMP certifications. |
| Viotonic Medication | Approved | Yes | Yes | Multiple | Holds multiple FDA approvals and maintains WHO-GMP and EU GMP certifications. |
| Movid Impex | Approved | Yes | Yes | Multiple | Holds multiple FDA approvals and maintains WHO-GMP and EU GMP certifications. |
| Rutva Medicare | Approved | Yes | Yes | Multiple | Holds multiple FDA approvals and maintains WHO-GMP and EU GMP certifications. |
TransData Nexus reviewed the regulatory standing of 9 leading Liraglutide exporters from India. 8 hold US FDA facility approvals, 9 maintain WHO-GMP certification, and 9 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Liraglutide sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Pharma City of India," is a pivotal hub for pharmaceutical manufacturing and research. The city contributes approximately 40% of India's bulk drug production and houses over 2,000 pharmaceutical companies. Notably, Hyderabad is home to major firms such as Aurobindo Pharma, Bharat Biotech, and Dr. Reddy’s Laboratories. The establishment of Genome Valley, a premier biotech cluster, has further solidified Hyderabad's position as a leader in life sciences innovation.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations. Gujarat accounts for 33% of India's drug manufacturing and 28% of drug exports, with Ahmedabad and Vadodara being central to this output. The region hosts prominent companies like Alembic Pharmaceuticals, Sun Pharma, and Cadila Pharmaceuticals. Vadodara, in particular, has evolved into a significant pharmaceutical hub, housing numerous large-scale industries and contributing substantially to the state's economy.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial gateway for pharmaceutical exports, leveraging its strategic coastal location and well-established port infrastructure. This region is home to several leading pharmaceutical companies, including Sun Pharmaceutical Industries Limited, which is the top exporter of Liraglutide, accounting for 52.6% of the total exports. The proximity to major ports facilitates efficient international distribution, making it a vital node in India's pharmaceutical supply chain.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing zone, primarily due to favorable tax incentives and supportive government policies. This area attracts numerous pharmaceutical companies seeking cost-effective production solutions, thereby contributing significantly to India's pharmaceutical output.
5Sourcing Recommendations
- Diversify Supplier Base: While SUN PHARMACEUTICAL INDUSTRIES LIMITED and ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED dominate Liraglutide exports, exploring partnerships with other manufacturers in regions like Hyderabad and Ahmedabad-Vadodara can mitigate supply chain risks.
- Leverage Regional Strengths: Utilize Hyderabad's expertise in bulk drug production for sourcing active pharmaceutical ingredients (APIs) and Ahmedabad-Vadodara's capabilities in formulations to optimize the supply chain.
- Optimize Logistics: Capitalize on the Mumbai-Thane-Raigad region's port facilities to streamline export processes and reduce lead times for international shipments.
- Monitor Regulatory Compliance: Ensure that suppliers in tax incentive zones like Baddi-Nalagarh adhere to all regulatory standards to maintain product quality and compliance.
By strategically engaging with these pharmaceutical clusters, TransData Nexus can enhance its supply chain resilience and efficiency in sourcing Liraglutide.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Liraglutide exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Concert Pharmaceuticals for $576 million
Sun Pharma completed the acquisition of Concert Pharmaceuticals, a late-stage biotechnology company, enhancing its specialty and innovative product portfolio. IMPACT: This acquisition is expected to bolster Sun Pharma's capabilities in specialty pharmaceuticals, potentially influencing its Liraglutide export strategies.
Impact: This acquisition is expected to bolster Sun Pharma's capabilities in specialty pharmaceuticals, potentially influencing its Liraglutide export strategies.
Sun Pharmaceutical Industries Limited — Sun Pharma acquires 60% stake in Vivaldis Animal Health
Sun Pharma acquired a majority stake in Vivaldis Animal Health and Foods, expanding its presence in the animal healthcare segment. IMPACT: While primarily focused on animal health, this diversification may indirectly affect Sun Pharma's resource allocation for Liraglutide exports.
Impact: While primarily focused on animal health, this diversification may indirectly affect Sun Pharma's resource allocation for Liraglutide exports.
Sun Pharmaceutical Industries Limited — Sun Pharma partners with Pharmazz for ischemic stroke drug in India
Sun Pharma entered into a licensing agreement with Pharmazz Inc. to introduce an ischemic stroke drug in the Indian market. IMPACT: This collaboration may enhance Sun Pharma's product offerings, potentially impacting its focus on Liraglutide exports.
Impact: This collaboration may enhance Sun Pharma's product offerings, potentially impacting its focus on Liraglutide exports.
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for $355 million
Sun Pharma announced the acquisition of Checkpoint Therapeutics, a company specializing in immunotherapy and targeted oncology treatments. IMPACT: This acquisition is likely to strengthen Sun Pharma's oncology portfolio, which may influence its strategic priorities, including Liraglutide exports.
Impact: This acquisition is likely to strengthen Sun Pharma's oncology portfolio, which may influence its strategic priorities, including Liraglutide exports.
Common Questions — Liraglutide Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which liraglutide supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with 15 recorded shipments worth $2.3M. ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMI (91 shipments) and LUPIN LIMITED (10 shipments) are also established high-volume exporters.
Q How many liraglutide manufacturers are there in India?
India has 53 active liraglutide exporters with a combined export market of $4.3M across 416 shipments to 36 countries. The top 5 suppliers hold 98.1% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for liraglutide from India?
Average FOB unit price: $35.91 per unit, ranging from $0.00 to $1000.00. Average shipment value: $10.3K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 53 verified Indian exporters of Liraglutide ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 416 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 36 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
416 Verified Shipments
53 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists